Sanyou Bio and Huadong Medicine Advance SYHD001 ADC Drug to Phase I Clinical Trials

17 July 2024 | Wednesday | News


Collaboration milestone highlights Sanyou Bio's innovative technology platforms and commitment to accelerating biopharmaceutical development.
Image Source : Public Domain

Image Source : Public Domain

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") has recently announced a significant milestone in collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963, hereinafter referred to as "Huadong Medicine"). The jointly developed ADC drug, designated as project number SYHD001, has successfully entered Phase I clinical trials. This important milestone not only signifies substantial progress in the collaboration between the two parties but also serves as a powerful testimony to the cutting-edge technology platform of Sanyou Bio.

SYHD001, as an ADC drug, presents extremely high technical demands and development complexities. Sanyou Bio has laid a solid foundation for the successful development of the drug from the outset with its three innovative platforms for biologic drugs: Super-trillion molecule discovery platform, Integrated R&D platform, and Intelligent R&D platform. Sanyou Bio completed the target research, raw material preparation, key molecule generation, assisted and cooperated in completing ADC conjugation and some in vitro and in vivo efficacy experiments, and helped the client to quickly and efficiently screen out compliant, high-expression, high-quality, and highly stable industrial cell lines for the project, thereby ensuring high-quality production and supply of ADC drugs and successfully promoting the project to rapidly complete IND filing and enter Phase I clinical trials.

Dr. Guojun LANG, CEO of Sanyou Bio, said "We are extremely honoured to collaborate with such an excellent partner as Huadong Medicine to advance SYHD001 to the clinical stage. In the future development, Sanyou Bio will continue to be committed to technological innovation and constantly enhance the core competitiveness of our own technology platform. We look forward to partnering with more collaborators to jointly promote the development of the biopharmaceutical industry and contribute more to the cause of human health."

Since its establishment in 2015, Sanyou Bio has provided systematic solutions from target to IND to accelerate the drug development process through five key categories of innovative biologic drug R&D. The five key R&D stage services include: Target Discovery and Raw Material Preparation, Molecule Generation, Molecule Optimization, Pharmacology and Efficacy Analysis, and Cell line Development and Production Process.

To date, Sanyou Bio has served 1,000+ pharmaceutical clients, 7 CPO projects have been obtained IND approval, 10+ projects are in the preclinical R&D stage, 26 collaborative R&D projects are progressing in manner. It has extensive experiences covering 100+ PCC projects and 300+ antibody drug discovery projects, and has cooperated or assisted partners in publishing more than 50 papers, including top journals such as CNS.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close